Published in Am J Respir Cell Mol Biol on January 08, 2009
Host responses in tissue repair and fibrosis. Annu Rev Pathol (2012) 2.10
Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chin J Cancer (2012) 1.01
The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms. Am J Pathol (2009) 0.99
Decreased caveolin-1 levels contribute to fibrosis and deposition of extracellular IGFBP-5. J Cell Mol Med (2011) 0.87
Mycophenolic acid inhibits migration and invasion of gastric cancer cells via multiple molecular pathways. PLoS One (2013) 0.85
Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Res Ther (2013) 0.81
Association between a functional polymorphism (-1195T>C) in the IGFBP5 promoter and head and neck cancer risk. Head Neck (2010) 0.81
Defining the disulfide bonds of insulin-like growth factor-binding protein-5 by tandem mass spectrometry with electron transfer dissociation and collision-induced dissociation. J Biol Chem (2011) 0.79
An ocular view of the IGF-IGFBP system. Growth Horm IGF Res (2013) 0.78
The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis. PLoS One (2014) 0.78
Insulin-like growth factor binding proteins-3 and -5: central mediators of fibrosis and promising new therapeutic targets. Open Rheumatol J (2012) 0.78
IGFBP-5 Promotes Fibrosis Independently of Its Translocation to the Nucleus and Its Interaction with Nucleolin and IGF. PLoS One (2015) 0.75
Local application of IGFBP5 protein enhanced periodontal tissue regeneration via increasing the migration, cell proliferation and osteo/dentinogenic differentiation of mesenchymal stem cells in an inflammatory niche. Stem Cell Res Ther (2017) 0.75
Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 24.36
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest (2004) 7.91
Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol (2004) 6.75
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med (1998) 6.22
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1998) 4.88
MAP kinases and cell migration. J Cell Sci (2004) 4.46
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today (1998) 4.21
CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol (2005) 4.02
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol (1991) 3.35
Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol (2004) 3.34
Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum (2000) 3.02
Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol (2005) 1.91
Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen (2007) 1.87
Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol (2003) 1.76
Alveolitis: the key to the interstitial lung disorders. Thorax (1982) 1.71
Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol (1993) 1.64
Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest (1996) 1.63
The IGF-I signaling pathway. Curr Pharm Des (2007) 1.60
Raf-1 regulates Rho signaling and cell migration. J Cell Biol (2005) 1.58
Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol (1998) 1.55
IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol (2002) 1.45
Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol (1993) 1.42
Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis (1991) 1.41
Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol (2007) 1.39
Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol (2006) 1.35
Evidence that IGF-binding protein-5 functions as a growth factor. J Clin Invest (2001) 1.32
Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum (1999) 1.25
B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum (2007) 1.24
Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am J Pathol (2005) 1.18
Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol (2006) 1.17
Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by Ras-dependent activation of p38 MAP kinase and Erk1/2 pathways. J Biol Chem (2002) 1.10
Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis. Arthritis Rheum (2006) 1.09
The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir Res (2001) 1.08
Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis (2005) 1.01
Fibronectin binds insulin-like growth factor-binding protein 5 and abolishes Its ligand-dependent action on cell migration. J Biol Chem (2003) 1.00
Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol (1998) 0.99
Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol (2006) 0.95
Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation. J Bone Miner Res (2005) 0.95
Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behçet's disease. Arthritis Rheum (2004) 0.95
Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J (1995) 0.94
Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. Am J Physiol (1997) 0.93
Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins. J Biol Chem (2003) 0.92
Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited. Chest (2003) 0.91
IGFBP-5(201-218) stimulates Cdc42GAP aggregation and filopodia formationin migrating mesangial cells. Kidney Int (2000) 0.89
Up-regulation of IL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis. Clin Exp Immunol (1997) 0.88
Bilateral bronchoalveolar lavage in progressive systemic sclerosis: interlobar variability, lymphocyte subpopulations, and functional correlations. Respiration (1991) 0.84
Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment. Intern Med J (2004) 0.82
Monocytic origin of fibrosis. In vitro transformation of HLA-DR monocytes into neo-fibroblasts: inhibitory effect of all-trans retinoic acid on this process. Biomed Pharmacother (1994) 0.77
Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med (2006) 2.92
Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A (2004) 2.42
Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med (2007) 2.17
Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol (2005) 1.91
Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest (2006) 1.76
Parallel mitral and tufted cell pathways route distinct odor information to different targets in the olfactory cortex. J Neurosci (2012) 1.75
Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol (2009) 1.45
Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol (2011) 1.44
Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum (2011) 1.33
Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum (2007) 1.33
B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum (2007) 1.24
Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol Cell Biol (2010) 1.19
Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol (2006) 1.17
The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum (2011) 1.13
MAPK pathway mediates EGR-1-HSP70-dependent cigarette smoke-induced chemokine production. Am J Physiol Lung Cell Mol Physiol (2007) 1.09
Insulin-like growth factor binding protein 5 induces skin fibrosis: A novel murine model for dermal fibrosis. Arthritis Rheum (2006) 1.09
The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One (2011) 1.02
Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol (2007) 1.02
The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol (2011) 1.00
Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum (2009) 0.99
The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms. Am J Pathol (2009) 0.99
Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins. Open Rheumatol J (2008) 0.98
Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol (2006) 0.97
Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. Arthritis Rheum (2012) 0.96
A peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med (2012) 0.96
Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol (2011) 0.96
Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum (2007) 0.96
Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. Hum Immunol (2004) 0.92
Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol (2013) 0.92
Insulin-like growth factor-II is increased in systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent pathways. Am J Pathol (2008) 0.90
A systems biology approach to genetic studies of complex diseases. FEBS Lett (2005) 0.90
Cigarette smoke stimulates matrix metalloproteinase-2 activity via EGR-1 in human lung fibroblasts. Am J Respir Cell Mol Biol (2006) 0.89
Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum (2005) 0.88
Oral administration of collagen tripeptide improves dryness and pruritus in the acetone-induced dry skin model. J Dermatol Sci (2012) 0.88
Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-κB and activator protein-1. Int J Biochem Cell Biol (2013) 0.88
Decreased caveolin-1 levels contribute to fibrosis and deposition of extracellular IGFBP-5. J Cell Mol Med (2011) 0.87
Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. Arch Dermatol Res (2011) 0.84
Unique charge distribution in surface loops confers high velocity on the fast motor protein Chara myosin. Proc Natl Acad Sci U S A (2009) 0.84
Role of insulin-like growth factor binding protein-3 in allergic airway remodeling. Am J Respir Crit Care Med (2009) 0.84
HIV gp120 induces mucus formation in human bronchial epithelial cells through CXCR4/α7-nicotinic acetylcholine receptors. PLoS One (2013) 0.83
Nosocomial infection of beta-lactam antibiotic-induced vancomycin-resistant Staphylococcus aureus (BIVR). J Infect Chemother (2006) 0.82
Investigation of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR). J Infect Chemother (2005) 0.82
Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Res Ther (2013) 0.81
Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease. Curr Rheumatol Rep (2010) 0.81
Autoimmunity in idiopathic pulmonary fibrosis: are circulating autoantibodies pathogenic or epiphenomena? Am J Respir Crit Care Med (2011) 0.80
Comprehensive analysis of gene expression on GOLD-2 Versus GOLD-0 smokers reveals novel genes important in the pathogenesis of COPD. Proc Am Thorac Soc (2006) 0.80
Update on scleroderma-associated interstitial lung disease. Curr Opin Rheumatol (2014) 0.80
Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis. PLoS One (2012) 0.80
Design and synthesis via click chemistry of 8,9-anhydroerythromycin A 6,9-hemiketal analogues with anti-MRSA and -VRE activity. Bioorg Med Chem Lett (2007) 0.79
Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis. Arthritis Res Ther (2013) 0.79
Insulin-like growth factor binding proteins-3 and -5: central mediators of fibrosis and promising new therapeutic targets. Open Rheumatol J (2012) 0.78
Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis Res Ther (2013) 0.78
Role of endostatin in fibroproliferative disorders.-as a candidate for anti-fibrosis therapy-. Nihon Rinsho Meneki Gakkai Kaishi (2013) 0.77
Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts. PLoS One (2012) 0.77
Editorial: molecular insights into systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol (2014) 0.77
Identification and characterization of the short variable region of the Japanese encephalitis virus 3' NTR. Virus Genes (2011) 0.77
Gene expression in pulmonary fibrosis. Crit Rev Eukaryot Gene Expr (2008) 0.76
Genetics of systemic sclerosis: recent advances. Curr Opin Rheumatol (2015) 0.75
IGF-I: mediator of fibrosis or carcinogenesis? Am J Physiol Lung Cell Mol Physiol (2005) 0.75
4'''-N-demethylspiramycin derivatives: synthesis and evaluation of effectiveness against drug-resistant bacteria. J Antibiot (Tokyo) (2008) 0.75
[Combination effect of pazufloxacin and anti-mrsa drugs against beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)]. Jpn J Antibiot (2005) 0.75